Eli Lilly and Company $LLY Holdings Decreased by Moody National Bank Trust Division

Key Points

• Moody National Bank Trust Division cut its stake in Eli Lilly by 31.4% in Q4, selling 3,183 shares and ending the quarter with 6,956 shares worth $7.475 million, making LLY its 20th largest holding.
• Eli Lilly posted strong Q4 results with $7.54 EPS (vs. $7.48 est.) and $19.29 billion in revenue (up 42.6% YoY), driven by robust GLP‑1 sales and management setting FY‑2026 guidance at $33.50–$35.00 EPS.
• Analyst sentiment remains positive despite rich valuation: consensus is a "Moderate Buy" with a $1,221.44 target, several firms raising price targets (JPMorgan $1,300, Barclays $1,350), and the stock trading at a P/E of ~39 and a market cap of ~$849 billion.

Moody National Bank Trust Division lowered its stake in Eli Lilly and Company (NYSE:LLY - Free Report) by 31.4% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 6,956 shares of the company's stock after selling 3,183 shares during the quarter. Eli Lilly and Company comprises about 0.7% of Moody National Bank Trust Division's portfolio, making the stock its 20th biggest holding. Moody National Bank Trust Division's holdings in Eli Lilly and Company were worth $7,475,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Exencial Wealth Advisors LLC lifted its holdings in shares of Eli Lilly and Company by 189.6% in the third quarter. Exencial Wealth Advisors LLC now owns 17,408 shares of the company's stock valued at $13,283,000 after buying an additional 11,396 shares during the period. Rede Wealth LLC acquired a new position in Eli Lilly and Company during the third quarter worth about $487,000. Central Pacific Bank Trust Division grew its holdings in Eli Lilly and Company by 25.8% during the third quarter. Central Pacific Bank Trust Division now owns 8,990 shares of the company's stock worth $6,859,000 after acquiring an additional 1,843 shares during the period. Cidel Asset Management Inc. raised its position in Eli Lilly and Company by 26.5% in the third quarter. Cidel Asset Management Inc. now owns 26,726 shares of the company's stock worth $20,392,000 after acquiring an additional 5,591 shares in the last quarter. Finally, Coldstream Capital Management Inc. raised its position in Eli Lilly and Company by 25.6% in the third quarter. Coldstream Capital Management Inc. now owns 42,418 shares of the company's stock worth $32,365,000 after acquiring an additional 8,659 shares in the last quarter. Institutional investors own 82.53% of the company's stock.

Eli Lilly and Company Price Performance

Shares of NYSE:LLY opened at $898.68 on Friday. The company's fifty day moving average is $1,010.46 and its two-hundred day moving average is $960.96. The company has a quick ratio of 1.19, a current ratio of 1.58 and a debt-to-equity ratio of 1.54. Eli Lilly and Company has a 12-month low of $623.78 and a 12-month high of $1,133.95. The company has a market cap of $849.09 billion, a P/E ratio of 39.16, a price-to-earnings-growth ratio of 1.06 and a beta of 0.40.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last issued its earnings results on Wednesday, February 4th. The company reported $7.54 EPS for the quarter, topping the consensus estimate of $7.48 by $0.06. Eli Lilly and Company had a return on equity of 102.94% and a net margin of 31.66%.The business had revenue of $19.29 billion during the quarter, compared to analysts' expectations of $17.85 billion. During the same quarter last year, the firm posted $5.32 earnings per share. Eli Lilly and Company's revenue was up 42.6% compared to the same quarter last year. Eli Lilly and Company has set its FY 2026 guidance at 33.500-35.000 EPS. Equities analysts expect that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Eli Lilly and Company News Summary

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Q4 earnings and revenue momentum — Coverage highlights Eli Lilly’s strong Q4 results and robust GLP‑1 sales that are driving top‑line and margin strength, supporting the company's growth story. Firing on All Cylinders: Eli Lilly NYSE: LLY Q4 Earnings Lead the Way
• Positive Sentiment: Bullish long‑term thesis on GLP‑1 leadership — Retail/bullish analysis argues that Lilly’s leadership in obesity/GLP‑1 drugs makes it a durable growth compounder, reinforcing investor enthusiasm. Could Buying Eli Lilly Today Set You Up for Life?
• Positive Sentiment: Analyst model tweak — Erste Group slightly raised FY‑2026 EPS expectations for LLY (minor lift to forecasts), which supports consensus that Lilly’s earnings power is rising. MarketBeat: Eli Lilly analyst note
• Neutral Sentiment: Media/celebrity endorsement and market performance — Jim Cramer and other outlets are naming Lilly among top healthcare picks, and recent trading showed short‑term outperformance, which can attract flows but also create volatility. Is Eli Lilly (LLY) The Best Healthcare Stock to Buy According to Jim Cramer?
• Neutral Sentiment: Industry comparisons and valuation debate — Analyst pieces compare LLY with peers (Novo Nordisk, ABBV), highlighting strong growth but also elevated multiples — important context for investors weighing upside vs. valuation risk. LLY or ABBV: Which Drugmaker is Likely to Offer Better Upside in 2026?
• Neutral Sentiment: Investor letters and fund commentary reiterate GLP‑1 as the growth engine, but also note concentration risk (revenue tied to a few franchises). Eli Lilly (LLY) Gained From Growth in its GLP-1 Franchises Drugs
• Negative Sentiment: Policy/reputation risk around GLP‑1s — Coverage raising the “societal obligation” and broader public debate about GLP‑1s can translate into regulatory scrutiny or reimbursement pressure, a potential near‑term headwind for sentiment. Eli Lilly and the ‘societal obligation’ of GLP-1s

Analyst Upgrades and Downgrades

Several equities analysts have recently weighed in on LLY shares. JPMorgan Chase & Co. raised their price objective on shares of Eli Lilly and Company from $1,150.00 to $1,300.00 and gave the company an "overweight" rating in a research report on Thursday, February 5th. Weiss Ratings reiterated a "buy (b-)" rating on shares of Eli Lilly and Company in a report on Monday, December 22nd. Barclays began coverage on shares of Eli Lilly and Company in a research note on Thursday, February 19th. They set an "overweight" rating and a $1,350.00 target price for the company. Loop Capital set a $1,200.00 price target on shares of Eli Lilly and Company in a research report on Tuesday, February 10th. Finally, Wolfe Research upped their price target on Eli Lilly and Company from $1,050.00 to $1,250.00 and gave the company an "outperform" rating in a report on Wednesday, December 3rd. Two research analysts have rated the stock with a Strong Buy rating, twenty-three have given a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $1,221.44.

About Eli Lilly and Company

Eli Lilly and Company NYSE: LLY is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.